ABSTRACT
prospectively enrolled 48 patients with well controlled HIV disease who had been on ATV for at 23 least 7 days. ATV was quantified from plasma using HPLC. A reversed-phase ultra high pharmacokinetic variability for identical dosing regimens (14, 33, 7, 31 whole blood, air-dried in the horizontal position and placed in sealed plastic bags for storage.
84
All samples were stored until study enrollment was complete at which time both DBS and 85 plasma samples were analyzed for ATV concentrations. All measurements of CD4 cell counts
86
and HIV-1 RNA were performed as part of standard patient care. The detection limit of the 87 HIV-1 RNA assay was 50 copies/mL.
88

Analytical Methods
89
The analysis of plasma ATV concentrations was performed using a previously developed extraction procedure using methyl tert-butyl ether at a basic pH was used to prepare the samples.
95
The chromatographic separation of the compounds and the internal standard was accomplished 96 on a YMC Octyl (C8) 120Ǻ, 100 x 4.6 mm column with a 3 micron particle size (Waters Corp., 
106
Our initial approach to development of a DBS method for ATV was to modify our HPLC 107 plasma assay for the DBS matrix. We tested our standard curve and measured a series of quality standard percent accuracy was ≤ 5.2% for standards above the LLOQ and 3.0% at the LLOQ.
113
The percent coefficient of variation (CV) was ≤ 6.3% above the LLOQ and 5.6% at the LLOQ.
114
The overall quality control variability was <5% for both percent CV and percent accuracy. The 115 overall validation sample percent accuracy was ≤ 6.5% above the LLOQ and 11.3% at the 116 LLOQ. The percent CV was ≤3.7% above the LLOQ and 6.7% at the LLOQ. These assay 117 validation data indicated assay performance characteristics consistent with our plasma assay subjects who had plasma HIV-RNA < 50 copies/mL with those who did not.
163
RESULTS
164
Patients
165
Forty eight patients consented to participate in this study. assay, which has been shown to be sufficient for pharmacokinetic studies in adults and children
228
(33,19). Finally, UPLC instrumentation has a considerably lower acquisition cost than a triple 229 quadruple mass spectrometer making it more readily available.
230
In the subjects who participated in this study, ATV concentrations were lower in those illustration of the utility of a DBS assay (6).
262
The utility of DBS samples may enhance the ability to evaluate ARV pharmacokinetics at that best predicts ARV response (1, 14) .
273
In conclusion, our study demonstrates that ATV quantitation in a DBS matrix is both 274 feasible and accurate, and may have utility in both clinical practice and pharmacokinetic studies.
275
Further evaluation of this technology is warranted for other antiretroviral agents. 
